Next generation targeted protein therapeutics

                                                                    Products

>  Product pipeline

Product Development Pipeline

Candidate	Lead Discovery	Pharmacology	Preclinical	Clinical
IGN001 Her2
IGN002 CD20				IND filling projected - 2012
IGN004 Melanoma/Solid tumors
IGN005 AML

IGN002:

Our lead candidate, IGN002, comprises an anti-CD20 monoclonal antibody attached to IFN through stable peptide linker system. CD20 is expressed on Non-Hodgkin lymphoma and other B cell driven hematologic malignancies. We have generated substantial preclinical data with IGN002, including data demonstrating that the targeting ability of IGN002 results in up to 100-fold higher than non-targeted IFN. Further, IGN002 also shows remarkable efficacy in rituximab resistant tumor models. These preclinical data demonstrate that IGN002 effectively targets and acts locally CD20- positive tumors.

IGN001:

Our second candidate, IGN001, comprises an anti-Her2 monoclonal antibody attached to IFN through stable peptide linker system. Her2 is expressed on breat cancer and other malignancies. We are in early stages of generating preclinical data with IGN001.

IGN004:

Our candidate, IGN004, comprises an monoclonal antibody against a novel target attached to IFN through stable peptide linker system. This target is expressed on multiple solid tumors and melanomas. We are in early stages of generating preclinical data with IGN004.

IGN005:

Our IGN005 candidate comprises an monoclonal antibody directed towards a well validated AML target attached to IFN through stable peptide linker system. This target is expressed on AML and other leukemias. We are in early stages of generating preclinical data with IGN005.